Discontinuation of Sickle Cell Disease Development for ASP8731/ML-0207
A standalone drug development program for the mitochondrial BACH1 inhibitor ASP8731/ML-0207, whose Phase 1 development for sickle cell disease was discontinued.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.